SIETES :: 93213 citas

Resultados de la búsqueda por INDICADORES REFINAR BÚSQUEDA

1.

Holloway KA, Henry D. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys . PLoS One 2014:16 de septiembre. [Ref.ID 98019]

2.

Corley DA, Jensen ChD, Marks AR, Zhao WK, Lee JK, Doubeni ChA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry ChP. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-306. [Ref.ID 97371]

3.

Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated initiation of ß-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med 2013;173:1547-9. [Ref.ID 96076]

4.

Morden NE, Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013;369:299-302. [Ref.ID 95875]

5.

Kale MS, Bishop TF, Federman AD, Keyhani S. Trends in the overuse of ambulatory health care services in the United States. JAMA Intern Med 2013;173:142-8. [Ref.ID 94819]

6.

Katz MH, Grady D, Redberg RF. Undertreatment improves, but overtreatment does not. JAMA Intern Med 2013;173:93. [Ref.ID 94815]

7.

Clark A, Briffa TG, Thirsk L, Neubeck L, Redfern J. What football teaches us about complex health interventions. BMJ 2012;345:25-7. [Ref.ID 94300]

8.

Jha AK, Classen DC. Getting moving on patient safety - Harnessing electronic data for safer care. N Engl J Med 2011;365:1756-8. [Ref.ID 91643]

9.

Angora Mazuecos F. Público/privado versus derecho/negocio en materia de salud. Revista Clínica de Medicina de Familia 2011;4:219-22. [Ref.ID 90666]

10.

Classen DC, Resar R, Griffin F, Federico F, Frankel T, Kimmel N, Whittington JC, Frankel A, Seger A, James BC. 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. Health Affairs 2011;30:581-9. [Ref.ID 90387]

11.

Vicens Caldentey C, Sempere Verdú E, Arroyo Aniés MP, Hernández Rodríguez MA, Palop Larrea V, Orueta Sánchez R, Baos Vicente V. Variabilidad en la medición de la calidad de prescripción por comunidades autónomas. Aten Primaria 2010;42:380-7. [Ref.ID 89142]

12.

Hassan NB, Ismail HC, Naing L, Conroy RM, Rahman ARA. Development and validation of a new Prescription Quality Index. Br J Clin Pharmacol 2010;70:500-13. [Ref.ID 89141]

13.

Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BHR, Denig P. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf 2010;19:abril. [Ref.ID 88266]

14.

Lilford R. Should the NHS strive to eradicate all unexplained variation? No. BMJ 2009;339:1172-3. [Ref.ID 87196]

15.

Richards S. Should the NHS strive to eradicate all unexplained variation? Yes. BMJ 2009;339:1172-3. [Ref.ID 87195]

16.

Fonarow GC, Peterson ED. Heart failure performance measures and outcomes. Real or illusory gains. JAMA 2009;302:792-4. [Ref.ID 86575]

17.

Esteban Calvo C, Ibáñez Ruiz C, Salgueiro Vázquez E, Manso Rodríguez G. Impacto de las recomendaciones del Sistema Español de Farmacovigilancia en la publicación de casos de reacciones adversas a medicamentos. Aten Primaria 2008;40:555-8. [Ref.ID 84874]

18.

Vlahovic-Palcevski V, Janhsen K, Elseviers M, Stichele RV. Cross national comparison of drug utilization research. Pharmacoepidemiol Drug Saf 2008;17:S117. [Ref.ID 84442]

19.

Font Noguera I, Pérez Cebrián M, Vázquez Polo A, Esteban Mensua MJ, Cercós Lletí AC, Poveda Andrés JL. Desarrollo de un sistema de indicadores en el área de farmacoterapia de un servicio de farmacia hospitalaria. Aten Farmaceutica 2008;10:7-20. [Ref.ID 82809]

20.

Anónimo. Consumo de medicamentos y productos sanitarios en el Sistema Nacional de Salud (2007). PAM 2008;32:275-80. [Ref.ID 82725]